Prehospital Whole Blood Transfusion Offers No Survival Benefit versus Component Therapy in Traumatic Hemorrhage: SWiFT Trial
UK: The SWiFT trial has found that prehospital transfusion of whole blood did not improve survival or reduce massive transfusion rates compared to component therapy in major traumatic hemorrhage. However, whole blood offered logistical benefits and demonstrated a favorable safety profile.
The findings, published in The New England Journal of Medicine, are from a large phase 3 randomized controlled trial led by Jason E. Smith of the Royal Centre for Defence Medicine. The study aimed to evaluate whether administering whole blood before hospital arrival could improve outcomes in patients with life-threatening traumatic bleeding.
Whole-blood transfusion has gained increasing attention in trauma care due to its simplicity and potential advantages over component therapy, which involves separate transfusion of red blood cells and plasma. However, robust clinical evidence comparing the two approaches in prehospital settings has been limited.
To address this, researchers conducted a multicenter, pragmatic trial across 10 air ambulance services in England. Patients with suspected major traumatic hemorrhage were randomly assigned to receive either up to two units of whole blood or standard component therapy (red blood cells and plasma) before reaching the hospital. The primary outcome was a composite of death from any cause or the need for massive transfusion within 24 hours.
Out of 942 randomized patients, 616 were included in the final analysis after excluding those with nontraumatic bleeding or cardiac arrest. Among these, 314 patients received whole blood, while 302 received standard care.
The trial revealed the following findings:
- No meaningful difference was observed between the two groups in the primary outcome.
- The primary outcome occurred in 48.7% of the whole-blood group and 47.7% of the standard-care group, indicating no superiority of whole blood.
- Mortality rates at all assessed time points were similar between both treatment groups.
- The need for massive transfusion was comparable between whole blood and component therapy.
- Secondary outcomes did not show significant differences, suggesting similar effectiveness of both approaches.
- The incidence of thrombotic complications was similar in both groups.
- Abnormal clotting parameters were more frequently noted in the whole-blood group.
- The number of serious adverse events was slightly lower in the whole-blood group compared to standard care.
- Overall findings support that prehospital whole-blood transfusion has a favorable safety profile.
Despite the lack of superiority in clinical outcomes, the study highlights important practical advantages of whole blood. Its use simplifies transfusion protocols and may improve efficiency in emergencies, particularly in resource-constrained or time-critical environments such as air ambulance services.
The authors note that while whole blood did not demonstrate improved survival or reduced transfusion needs, its logistical benefits and comparable safety profile make it a viable alternative to component therapy. Further research may help identify specific patient groups or scenarios where whole blood could offer greater clinical benefit.
Overall, the SWiFT trial provides important evidence to guide trauma care practices, indicating that while whole blood is safe and practical, it does not confer additional survival advantages over standard component-based transfusion in patients with major traumatic hemorrhage.
Reference:
Smith JE, Cardigan R, Sanderson E, Silsby L, Rourke C, Barnard EBG, Basham P, Antonacci G, Charlewood R, Dallas N, Davies J, Goodwin E, Hawton A, Hudson C, Lucas J, Keen K, Lyon RM, Nolan B, Perkins GD, Rundell V, Smith L, Stanworth SJ, Weaver A, Woolley T, Green L; SWiFT Trial Group. Prehospital Whole Blood in Traumatic Hemorrhage - a Randomized Controlled Trial. N Engl J Med. 2026 Mar 17. doi: 10.1056/NEJMoa2516043. Epub ahead of print. PMID: 41841706.
Next Story